



March 2, 2021

OASAS Guidance Regarding SARS-CoV-2 Point of Care (POC) Antigen (Ag) Testing in Inpatient and Residential Settings and Opioid Treatment Programs (OTPs)

This guidance provides information on SARS-CoV-2 (COVID-19) POC Ag testing for New York State (NYS) Office of Addiction Services and Supports (OASAS) licensed, funded, and operated inpatient and residential programs and OTPs.

General Information

The Abbott BinaxNOW COVID-19 Ag Card is a waived POC SARS-CoV-2 diagnostic test. The test must be ordered by a qualified healthcare provider (including physicians, physician assistants, and nurse practitioners).

The instructions specify use of the test on direct nasal swabs (one swab of both nares/nostrils – see specific instructions for use available at <https://www.fda.gov/media/141570/download>. For additional information, also see <https://www.globalpointofcare.abbott/en/product-details/navica-binaxnow-covid-19-us.html> under Helpful Documents). This test does not require an instrument.

The Abbott BinaxNOW COVID-19 Ag Card is intended to be used for the detection of SARS-CoV-2 in individuals who are suspected of COVID-19 by their healthcare provider, within the first seven days of the onset of symptoms. Although these tests have not been approved by the United States Food and Drug Administration (FDA) for use on asymptomatic individuals, the Centers for Medicare and Medicaid Services (CMS) will temporarily exercise enforcement discretion for the duration of the COVID-19 public health emergency under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and will allow the use of SARS-CoV-2 POC Ag tests, including the Abbott BinaxNOW COVID-19 Ag Card, on asymptomatic individuals.

Ag levels in specimens collected beyond 7 days of the onset of symptoms may drop below the limit of detection of the test. This may result in a negative test result, while a more sensitive laboratory-based SARS-CoV-2 molecular test may produce a positive result on the same specimen. Therefore, negative results from symptomatic patients should be treated as presumptive negative and confirmed with a laboratory-based SARS-CoV-2 molecular assay. **See below for additional information on interpreting SARS-CoV-2 POC Ag test results when testing symptomatic or asymptomatic individuals.**

SARS-CoV-2 (COVID-19) POC Ag Testing:

SARS-CoV-2 (COVID-19) POC Ag tests are being provided to NYS OASAS licensed, funded, and operated programs at no charge, pending availability of testing supplies.

For detailed information regarding SARS-CoV-2 POC Ag testing issued by the NYS Department of Health (DOH), including a SARS CoV-2 POC Antigen Testing FAQ ([here](#)), Interim Recommendations for Use of

501 7th Avenue | New York, New York 10018-5903 | oasas.ny.gov | 646-728-4760

1450 Western Avenue | Albany, New York 12203-3526 | oasas.ny.gov | 518-473-3460



Office of Addiction Services and Supports

ANDREW M. CUOMO

Governor

ARLENE GONZÁLEZ-SÁNCHEZ, M.S., L.M.S.W.

Commissioner

SARS-CoV-2 Antigen Tests During COVID-19 Public Health Emergency ([here](#)), and SARS-CoV-2 Antigen Tests Algorithm ([here](#)), see the preceding links.

The above referenced documents follow a **very clear algorithm** on **how to interpret the SARS-CoV-2 POC Ag test result depending on whom you are testing (an asymptomatic patient v. symptomatic patient), under what circumstances (in the context of an outbreak in a congregate setting or not), and when the SARS-CoV-2 POC Ag test must be followed up with a diagnostic SARS-CoV-2 molecular test for a definitive diagnosis of COVID-19.**

There are several key considerations when planning to implement SARS-CoV-2 POC Ag testing in OASAS settings, including safety and training, in house laboratory issues, testing supplies, reporting of results, maintenance of records, interpretation and application of test results, linking patients to SARS-CoV-2 molecular diagnostic testing when indicated, and recommendations on the frequency of testing in your individual setting. Programs should work with their medical and nursing leadership to develop policies and protocols to reflect these key considerations.

Safety and Training

1. All healthcare personnel collecting nasal (anterior nares) swab samples should utilize appropriate PPE, including a fit-tested N95 or higher-level respirator (or face mask if a respirator is not available), eye protection (goggles or a face shield that covers the front and sides of the face), gowns, and gloves if testing is done by a tester and within 6 feet of the patient. If the patient self swabs and the observing, trained healthcare personnel is not within 6 feet of the patient, then only a face mask and gloves are indicated for the observing healthcare personnel. This is a strategy for minimizing PPE use. See [Training for Sample Collection Procedure for SARS-CoV-2 Diagnostic Testing](#) (slides 16 thru 22 and slide 32), and CDC guidance [here](#), and [here](#).
2. The laboratory director (or designee) at your institution should read the Instructions for Use in the Abbott BinaxNOW COVID-19 Ag Card (<https://www.fda.gov/media/141570/download>). Any staff performing testing need to be properly trained and their competency assessed. Competency assessment is a process to make sure that staff are following the proper test procedure after initial training and should be performed at least annually and should be documented.

Training videos, modules, helpful documents and frequently asked questions for the BinaxNOW™ test can be accessed on Abbott's website:

<https://www.globalpointofcare.abbott/en/support/product-installation-training/navica-brand/navica-binaxnow-ag-training.html>. All training modules must be completed. Observation of proper specimen collection and test performance and interpretation, using a positive and negative control, must be completed prior to testing patients. Sites not using the NAVICA app QR code (*see below) to identify the card as corresponding to a specific tested individual must have a means to uniquely identify the patient's card to avoid a test mix-up.

Watch Abbott BinaxNOW sample collection technique video [here](#) (under Helpful Documents

501 7th Avenue | New York, New York 10018-5903 | oasas.ny.gov | 646-728-4760

1450 Western Avenue | Albany, New York 12203-3526 | oasas.ny.gov | 518-473-3460



Office of Addiction Services and Supports

ANDREW M. CUOMO

Governor

ARLENE GONZÁLEZ-SÁNCHEZ, M.S., L.M.S.W.

Commissioner

->Videos)

For questions regarding the BinaxNOW™ test, please call Abbott Technical Services at 1-800-257-9525 or email ts.scr@abbott.com.

- a. Staff should be trained in the proper donning and doffing of PPE. See [CDC Using Personal Protective Equipment](#) and [Training for Sample Collection Procedure for SARS-CoV-2 Diagnostic Testing](#) (slides 24 and 25).
- b. Programs should contact their [local health department and/or their OASAS Regional Office \(RO\) or State Opioid Treatment Authority \(SOTA\)](#) if they need assistance in identifying existing resources for fit testing for respirator masks.

All staff collecting samples should be properly trained in safe sample collection techniques. Watch Abbott BinaxNOW sample collection technique video [here](#) (under Helpful Documents ->Videos). See [Training for Sample Collection Procedure for SARS-CoV-2 Diagnostic Testing](#) (slides 26 thru 37).

***NAVICA app:**

Abbott offers a phone app reporting system. The patient downloads the consumer app and the testing site can use the NAVICA Administrator App to pair a patient to a test card and to communicate encrypted BinaxNOW™ COVID-19 Ag Card test results to participants. The NAVICA Administrator app is designed to be used on a computer tablet. See the Abbott website for details.

It is not required that the NAVICA app be used. The results of the test can be recorded manually, and the report provided to the individual tested as per state requirements and your laboratory's procedures. All results must also be reported to the NYS Department of Health (see page 5 below).

3. Non-medical, unlicensed staff may collect anterior nares specimens if properly trained. See [DOH Specimen Collection Training for Unlicensed Individuals](#).
4. Test samples should be handled properly and transported to the in-house laboratory for processing. Please note that the BinaxNOW™ COVID-19 Ag Card instructions for Use state that direct nasal swabs should be tested as soon as possible after collection and provide instructions on the transport and handling specimens if they cannot be immediately tested.
5. The physical space where test samples are collected should have adequate ventilation, which should be discussed with and approved by the local department of health (or infection control department for hospital-based programs) before beginning test sample collection. Test samples can also be safely collected outdoors. Sample collection should never be done in shared client rooms.
6. Policies and protocols should be in place to ensure that the number of health care personnel present during the procedure should be limited only to those essential for patient care and procedure support (i.e., the person collecting the sample) during sample collection, and that the room is properly sanitized afterwards. Visitors should not be present for specimen

501 7th Avenue | New York, New York 10018-5903 | oasas.ny.gov | 646-728-4760

1450 Western Avenue | Albany, New York 12203-3526 | oasas.ny.gov | 518-473-3460



collection. **Non-aerosol-generating procedures (e.g., interviewing) should be performed before any procedures that may lead to coughing or sneezing. Collecting NP/OP/anterior nares specimens should be the last activity performed just before leaving the room.** The potential for aerosolization exists with nasal (anterior nares) swabs as the procedure may generate a cough or sneeze. As indicated above, if a staff member is doing the nasal (anterior nares) swab, full PPE must be worn. If the patient self swabs and the observing, trained healthcare personnel is not within 6 feet of the patient, then only a face mask and gloves are indicated for the observing healthcare personnel. This is a strategy for minimizing PPE use.

7. Patients should not be transported by staff or be accompanied on public transit solely for the purposes of test sample collection, as this could increase exposure to COVID-19 for staff, other patients, and the community.
8. See [CDC Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens for COVID-19](#), [Training for Sample Collection Procedure for SARS-CoV-2 Diagnostic Testing](#), and [here \(slides 18-43\)](#).

Limited Services Lab (LSL) Issues

- Only facilities that have, at a minimum, an LSL certification may perform SARS-CoV-2 POC Ag testing. The LSL certificate for the facility must be current. For more information on becoming an LSL, see the OASAS FAQ [here](#). See LSL application materials [here](#). To determine if your facility is an LSL, check [here](#).
- If your facility already has a current LSL, you must add the SARS-CoV-2 POC Ag test to your LSL registration. The Laboratory Director or designee at your facility, must fill out and submit the Change Test Request Form immediately so that your use of the test is not delayed. Information on adding COVID-19 test to an existing LSL can be found [here](#). Click on “COVID-19 Response for Limited Service Laboratory Registration Requests and Additions” and follow the instructions provided. The NYS DOH has agreed to accept an email with an attachment of a high-quality scan of the signed change request form (instead of using the US mail) to submit the form. The email address is clepltd@health.ny.gov. See [here](#).
- To assist the DOH Clinical Laboratory Evaluation Program (CLEP) to triage incoming emails, please provide the following information in the Subject Line of your email: your PFI# and the test(s) that you wish to add, for example: **PFI#: _____ - Request to Add COVID-19 Abbott BinaxNOW COVID-19 Ag Cards**
- For general information on SARS-CoV-2 (COVID-19) testing and the LSL, see the CLEP page [here](#). If testing will occur at a location other than the address shown on the LSL registration, the LSL must request approval to perform Community Screening. Next to test procedure name, indicate “request Off-Site Community Screening approval.”

If an LSL wants to do testing at off-site Community Screening events, they must request Community Screening approval. Laboratory staff bring testing equipment from the registered LSL to an off-site location where specimen collection and testing will occur. At the end of the

501 7th Avenue | New York, New York 10018-5903 | oasas.ny.gov | 646-728-4760

1450 Western Avenue | Albany, New York 12203-3526 | oasas.ny.gov | 518-473-3460



event, staff, equipment and records return to the registered LSL location. If a facility does not want to perform testing using the Abbott BinaxNOW COVID-19 Ag Card, the facility can partner with another facility that has NYS approval to use this test for community screening.

Testing Supplies

OASAS will be requesting the Abbott BinaxNOW testing supplies from NYS on behalf of the OASAS programs. Testing supplies will be distributed to programs, and more information about this will be provided to your designated LSL point of contact.

Receipt and Storage of Kits:

Each kit contains 40 tests. Note the expiration date on each kit. All kits coming in a shipment should be noted as quality control testing is required for each shipment.

The kits should be stored at room temperature (2-30° C = 35.6 - 86-30°F).

Disposal of Test Card:

The card should be disposed of as regulated medical waste (using a biohazard red bag).

Interpretation and Application of Test Results

All tests have limitations, including false positive and false negative rates. Results should be used in conjunction with other clinical data including symptoms and history of COVID-19 contacts to inform clinical decision-making.

As with any test, the prior probability of infection should be considered (e.g., symptomology, prevalence in the region, history of contact with a positive person, travel history, presence at an event associated with an outbreak, etc.). Please read the SARS-CoV-2 POC Antigen Testing FAQ ([here](#)) and follow the SARS-CoV-2 Antigen Tests Algorithm ([here](#)). Additional guidance from the CDC on rapid antigen testing for SARS-CoV-2 can be found [here](#) and includes information on the relationship between pre-test probability and the likelihood of positive and negative predictive values. Each testing site should have a plan for obtaining confirmatory laboratory-based molecular testing when it is indicated and should consult a healthcare provider if questions arise in interpretation of a test result. Note, there is limited data on the performance of this test in asymptomatic individuals infected with the virus.

The NYS DOH has issued clear guidance on interpreting SARS-CoV-2 POC Ag testing dependent on symptoms and the setting, see documents [here](#), [here](#), [here](#), and [here \(slides 19-26\)](#).

Important considerations in the context of using the SARS-CoV-2 POC Ag testing include the following: Is a COVID-19 outbreak occurring in the general public? Is an outbreak occurring in my facility (i.e., is there a positive COVID-19 case in patients or staff members within the facility)? Is the person being tested symptomatic (with COVID-19 like symptoms) or



asymptomatic? Where will I refer the patient for molecular testing if indicated to do so by the NYS DOH algorithm?

Reporting of Results:

All facilities with an LSL who are performing SARS-CoV-2 Ag tests are required to report test results to the Commissioner through the Electronic Clinical Laboratory Reporting System (ECLRS). As noted in guidance that OASAS issued with the NYS Office of Mental Health, [OMH and OASAS Ambulatory and Residential Program COVID-19 Testing, Record Keeping, and Notification Instructions](#), all consent forms must be updated to include the possibility of reporting confirmed or suspected COVID-19 to the NYS DOH and local health departments.

What information needs to be reported?

All results, including positive, negative, and indeterminate results need to be reported. In addition, facilities performing SARS-CoV-2 Ag testing are required to report:

- test type;
- test result including positive and negative results;
- test result date;
- accession number;
- patient age;
- patient race;
- patient ethnicity;
- patient sex;
- patient name;
- patient's complete phone number;
- patient date of birth;
- full patient address where currently residing;
- county;
- ordering provider name;
- ordering provider address with zip;
- ordering provider phone number;
- performing facility name and CLIA number;
- performing facility zip code (full address);
- specimen source;
- date specimen collected;
- patient's occupation;
- patient's employer name;
- patient's work address;
- patient's employer phone number;
- whether the person being tested attends, works or volunteers in a school and if so, the name and location of the school. This includes elementary, secondary and post-

501 7th Avenue | New York, New York 10018-5903 | oasas.ny.gov | 646-728-4760

1450 Western Avenue | Albany, New York 12203-3526 | oasas.ny.gov | 518-473-3460



Office of Addiction Services and Supports

ANDREW M. CUOMO

Governor

ARLENE GONZÁLEZ-SÁNCHEZ, M.S., L.M.S.W.

Commissioner

secondary/higher education. For minors, the detailed information can be entered in the occupation and employment fields.

How often are test results reported?

All facilities performing testing for COVID-19 must report test results immediately within 24 hours through ECLRS.

How are test results reported?

Results can be reported to ECLRS by file upload or by manual entry into ECLRS. Please contact the ECLRS Help Desk at (866) 325-7743 or eclrs@health.ny.gov with any technical questions.

Maintenance of Records:

Any records associated with the use of this test must be maintained until otherwise notified by the FDA. Such records will be made available to the FDA for inspection upon request (see the Abbott BinaxNOW COVID-19 Ag Card Instruction card).

Linking Patients Who Need SARS-CoV-2 Molecular Diagnostic Testing When Indicated:

If your facility does not have the capacity to do SARS-CoV-2 molecular diagnostic testing on site when indicated (see [here](#), [here](#), and [here](#) for indications), then there need to be policies, procedures, and linkage agreements in place for patients to receive appropriate testing in a timely manner. See [here](#) to locate a COVID-19 test site near you. Your local health department may have further COVID-19 testing resources available.

Recommendations on Frequency of Testing:

The guidance regarding use of SARS-COV2 POC Ag testing continues to evolve. OASAS will work with the NYS DOH to provide updated guidance as it becomes available. There is no clear precedent on how and when to utilize SARS-CoV-2 POC Ag testing in substance use disorder (SUD) treatment settings. The following recommendations will be used to determine the amount of testing supplies that programs are allocated. Each individual facility or OTP should develop policies and procedures that address their unique practice setting.

Recommendations for inpatient rehabilitation and detoxification settings, and in 820 stabilization and rehabilitation programs:

For inpatient rehabilitation and detoxification settings, and in 820 stabilization and rehabilitation programs, use the POC Ag test to test all patients at admission, anyone who develops symptoms consistent with COVID-19, those who have been exposed to a known COVID-19 case (either exposure within the facility and/or outside of the facility). If there is a confirmed case of COVID-19 within the facility among either a patient or a staff member, immediate isolation of the positive individual(s) will need to occur. In addition, facilities will need to conduct a case investigation to identify direct contacts to the case(s) in need of testing and quarantine, and will need to restrict movement within the impacted facility unit(s) or facility-wide, as appropriate, in consultation with the local health

501 7th Avenue | New York, New York 10018-5903 | oasas.ny.gov | 646-728-4760

1450 Western Avenue | Albany, New York 12203-3526 | oasas.ny.gov | 518-473-3460



Office of Addiction Services and Supports

ANDREW M. CUOMO

Governor

ARLENE GONZÁLEZ-SÁNCHEZ, M.S., L.M.S.W.

Commissioner

department. The same process will occur again if any breach in infection control protocols occurs while individuals are under isolation protocol.

Recommendations for longer term residential settings (i.e., all 819 and 820 reintegration programs):

For longer term residential settings (i.e., all 819 and 820 reintegration programs), test in outbreak situations only. If the facility has a confirmed COVID-19 case within the facility among either a resident or a staff member, then test all residents in the facility. The OASAS RO should be contacted in either situation to request that testing supplies are deployed to the residential facility.

Recommendations for OTPs: In the absence of active community spread of COVID-19, OTPs can consider using SARS-CoV-2 POC Ag testing in twice monthly testing events on randomly selected days. The frequency of the testing events may be informed by how many patients come on any given day, i.e., if fewer patients attend on a given day, then perhaps schedule testing events more frequently. This strategy might include selecting different days of the week to do testing events in order to offer testing to individuals on different dosing/pick-up days. On selected days, testing should be offered to any patient who presents to the OTP. This is an attempt to capture as many different patients over time without depleting testing supplies/resources or creating undue OTP staff burden. Other approaches might be considered and discussed with OASAS (RO and SOTA) for input.

If there is a confirmed case of COVID-19 that impacts the OTP among either a patient or a staff member, contact tracing efforts in conjunction with the local health department (LHD) will inform testing recommendations for patients and staff at the OTP.

OTPs should not BRING patients in FOR TESTING when there is an outbreak at the OTP. In the context of an outbreak at the OTP, the OTP should focus on reducing visits to the OTP as appropriate and per previous guidance (i.e., through increased use of take home doses, telehealth, designated others, methadone delivery system in NYC, etc.).

501 7th Avenue | New York, New York 10018-5903 | oasas.ny.gov | 646-728-4760

1450 Western Avenue | Albany, New York 12203-3526 | oasas.ny.gov | 518-473-3460